What is the prevalence of Afibrinogenemia?
How many people does Afibrinogenemia affect? Does it have the same prevalence in men and women? And in the different countries?
Afibrinogenemia is a rare inherited bleeding disorder characterized by the absence or severe deficiency of fibrinogen, a protein essential for blood clotting. It is estimated to affect approximately 1 in 1-2 million individuals worldwide. The disorder is inherited in an autosomal recessive manner, meaning that both parents must carry a mutated gene for their child to be affected. Symptoms may include spontaneous bleeding, easy bruising, and prolonged bleeding after injury or surgery. Prompt diagnosis and appropriate management are crucial to prevent complications and ensure optimal quality of life for individuals with afibrinogenemia.
Afibrinogenemia is a rare inherited bleeding disorder characterized by the absence or severe deficiency of fibrinogen, a protein essential for blood clotting. It is estimated that the prevalence of afibrinogenemia is approximately 1 in 1-2 million individuals worldwide.
The disorder is inherited in an autosomal recessive manner, meaning that both parents must carry a copy of the mutated gene for their child to be affected. Symptoms of afibrinogenemia can vary widely, ranging from mild bleeding tendencies to life-threatening hemorrhages.
Due to its rarity, afibrinogenemia often goes undiagnosed or misdiagnosed. Genetic testing is necessary to confirm the diagnosis. Treatment typically involves replacement therapy with fibrinogen concentrates or cryoprecipitate to prevent or control bleeding episodes.
Research and advancements in medical technology have improved the management of afibrinogenemia, providing affected individuals with better quality of life. However, due to its low prevalence, further studies and awareness are needed to better understand and support individuals with this rare bleeding disorder.
